<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1134">
  <stage>Registered</stage>
  <submitdate>18/04/2006</submitdate>
  <approvaldate>18/04/2006</approvaldate>
  <nctid>NCT00316264</nctid>
  <trial_identification>
    <studytitle>Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season</studytitle>
    <scientifictitle>A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MI-CP127</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory Syncytial Virus Infections</healthcondition>
    <healthcondition>Chronic Lung Disease and &lt;= 24 Months of Age or</healthcondition>
    <healthcondition>Premature With Gestational Age &lt;=35 Weeks and &lt;=6 Months of Age</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Motavizumab, palivizumab
Other interventions - Palivizumab, motavizumab
Other interventions - Motavizumab

Experimental: Motavizumab followed by Palivizumab - 2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)

Experimental: Palivizumab followed by motavizumab - 2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)

Experimental: Motavizumab control - 5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)


Other interventions: Motavizumab, palivizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.

Other interventions: Palivizumab, motavizumab
Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.

Other interventions: Motavizumab
Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Subjects Reporting Serious Adverse Events (SAEs)</outcome>
      <timepoint>Day 0 - Day 150</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Subjects Reporting Adverse Events (AEs)</outcome>
      <timepoint>Day 0 - Day 150</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs. - Serum chemistry samples were collected at Day 0, Day 60, and Day 150. Values representing changes in severity according to the AE grading table were recorded as AEs.</outcome>
      <timepoint>Day 0 - Day 150</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The Serum Concentrations of Motavizumab at Day 0</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Trough Serum Concentrations of Motavizumab at Day 60</outcome>
      <timepoint>Day 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Trough Serum Concentrations of Motavizumab at Day 150</outcome>
      <timepoint>Day 150</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose</outcome>
      <timepoint>120-150 days post final dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Serum Concentrations of Palivizumab at Day 0</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Trough Serum Concentrations of Palivizumab at Day 60</outcome>
      <timepoint>Day 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Trough Serum Concentrations of Palivizumab at Day 150</outcome>
      <timepoint>Day 150</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose</outcome>
      <timepoint>120-150 days post final dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Motavizumab at Day 0 - Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Motavizumab at Day 60 - Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>Day 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Motavizumab at Day 150 - Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>Day 150</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose - Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>120 - 150 days post final dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Motavizumab at Any Time - Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>At any time</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Palivizumab at Day 0 - Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Palivizumab at Day 60 - Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>Day 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Palivizumab at Day 150 - Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>Day 150</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose - Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>120 - 150 days post final pose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Immunogenicity of Palivizumab at Any Time - Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</outcome>
      <timepoint>At any time</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The child must have been born at less than or equal to 35 weeks gestation and be less
             than or equal to 6 months of age at the time of entry into the study (child must be
             entered on or before his/her 6-month birthday); or the child must be less than or
             equal to 24 months of age at the time of entry into the study (child must be entered
             on or before his/her 24-month birthday) and diagnosed with chronic lung disease (CLD)
             of prematurity with stable or decreasing doses of diuretics, steroids, or
             bronchodilators, or treatment with supplemental oxygen, within the previous 6 months.

          -  The child must be in general good health at the time of study entry.

          -  The child's parent(s)/legal guardian must provide written informed consent.

          -  The child must be able to complete the follow-up visits through 120-150 days from last
             injection of study drug.

          -  Parent(s)/legal guardian of patient must have available telephone access.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Hospitalized at the time of study entry (unless discharge is expected within 10 days
             after entry into the study)

          -  Receiving chronic oxygen therapy or mechanical ventilation at the time of study entry
             (including continuous positive airway pressure [CPAP])

          -  Congenital heart disease (CHD) (children with medically or surgically corrected
             [closed] patent ductus arteriosus and no other CHD may be enrolled)

          -  Evidence of infection with hepatitis A, B, or C virus

          -  Known renal impairment, hepatic dysfunction, chronic seizure disorder, or
             immunodeficiency or HIV infection (a child of a mother with known HIV infection must
             be proven to be uninfected at the time of enrollment)

          -  Suspected serious allergic or immune-mediated events with prior receipt of palivizumab

          -  Acute illness or progressive clinical disorder

          -  Active infection, including acute RSV infection, at the time of enrollment

          -  Previous reaction to intravenous immunoglobulin (IGIV), blood products, or other
             foreign proteins

          -  Received within the past 120 days or currently receiving immunoglobulin products (such
             as RSV-IGIV [RespiGam], IVIG, or palivizumab) or any investigational agents

          -  Previous participation in a clinical trial of motavizumab

          -  Currently participating in any investigational study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>260</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Department of Paediatrics and Child Health, The Canberra Hospital - Garran</hospital>
    <hospital>Neonatalogy John Hunter Hospital - New Lambton Heights</hospital>
    <hospital>Caboolture Clinical Research - Caboolture</hospital>
    <hospital>University of Queensland, Royal Children's Hospital - Herston</hospital>
    <hospital>Peninsula Clinical Research Centre - Kippa-Ring</hospital>
    <hospital>Women's and Children's Hospital - North Adelaide</hospital>
    <hospital>Respiratory Medicine Department, Royal Children's Hospital - Parkville</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>4510 - Caboolture</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4021 - Kippa-Ring</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedImmune LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and
      palivizumab were administered sequentially to high-risk children during the same respiratory
      syncytial virus (RSV) season. A control group was administered only motavizumab.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00316264</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pamela Griffin, M.D.</name>
      <address>MedImmune LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>